Dare Bioscience (DARE) Stock: Buy, Sell, or Hold?
DARE - Dare Bioscience, Inc. Common Stock
$0.84
-0.01 (-0.96%)
âŧ
5d:
+8.68%
30d:
+13.89%
90d:
-59.48%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When DARE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: DARE is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: DARE is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: DARE is currently trading at $0.84, which is considered slightly low relative to its 30-day fair value range of $0.72 to $0.80. From a valuation perspective, the stock is trading at a discount (Forward PE: -2.0) compared to its historical average (3.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DARE is in a strong downtrend. Immediate support is located at $0.70, while resistance sits at $0.88.
Market Sentiment: DARE scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.33 (+888.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DARE is in a strong downtrend. Immediate support is located at $0.70, while resistance sits at $0.88.
Market Sentiment: DARE scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.33 (+888.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.72 -
$0.80
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (10/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 888.8% below Wall St target ($8.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 33/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.72 -
$0.80
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.70
Resistance Level
$0.88
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.03
Wall Street Target
$8.33
(+888.8%)
Revenue Growth (YoY)
499.6%
PE vs Historical
-2.0 vs 3.6
CHEAP
Share & Embed Analysis
Last updated: October 03, 2026 2:42 PM ET
Data refreshes hourly during market hours. Next update: 3:42 PM
Data refreshes hourly during market hours. Next update: 3:42 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DARE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
